23 . 03 .2026
Press release
Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing
20 . 03 .2026
Press release
Galderma publishes invitation and agenda for its 2026 Annual General Meeting
17 . 03 .2026
News story
AMWC Monaco 2026: Galderma’s scientific presentations and activities
17 . 03 .2026
Press release
AMWC 2026: Galderma showcases category‑leading innovation with a comprehensive portfolio and holistic, future‑focused aesthetic strategies
11 . 03 .2026
Press release
Galderma completes successful placement of EUR 500 million Eurobond
11 . 03 .2026
Press release
Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering
09 . 03 .2026
Press release
Galderma introduces Cetaphil AM/PM Antioxidant Serums, a new science-driven defense and recovery system for sensitive skin
05 . 03 .2026
Press release
Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency
27 . 02 .2026
Press release
Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years